The cardiovascular health of prisoners who use cannabis: An exploratory study among hospitalised prisoners.

Addictovigilance Cannabis Cardiovascular diseases Drug-related side effects and adverse reactions Harm reduction Hospitalisation Prisons

Journal

Therapie
ISSN: 1958-5578
Titre abrégé: Therapie
Pays: France
ID NLM: 0420544

Informations de publication

Date de publication:
Historique:
received: 13 05 2020
revised: 09 06 2020
accepted: 18 06 2020
pubmed: 29 7 2020
medline: 18 9 2021
entrez: 29 7 2020
Statut: ppublish

Résumé

It is essential that health professionals who practice medicine in prison rely on accurate knowledge about their patients to provide them with adapted care. The use of cannabis can influence the health status of prisoners, but data are lacking regarding the potentially related adverse health consequences. The objective of this descriptive study was to describe the cardiovascular outcomes related to cannabis use in prisoners from several detention centres hospitalised in a French hospital. In France, prisoners who require a longer than 48-hour hospitalisation are admitted in specific secured polyvalent units called inter-regional secured hospital units (ISHU). Hospitalisations in the ISHU of Toulouse University Hospital between 2012 and 2016 for cardiovascular disorders potentially related to the use of cannabis were extracted from the French hospital database and analysed using a previously validated methodology. Included patients were those hospitalised for an inaugural cardiovascular event or deterioration of a preexisting cardiovascular illness who declared having used cannabis while imprisoned. Overall, 31 cardiovascular outcomes were identified in cannabis-using hospitalised prisoners among 411 hospitalisations for cardiovascular disorders (all men, mean age 43±SD years old). All used cannabis (daily: 56%) and tobacco (more than 15 PY: 83.3%), 5 used cocaine, and none used alcohol. The most frequent were coronaropathy (n=13), followed by obliterating arteriopathy of the lower limb (OALL, n=7), arrhythmic cardiomyopathy (n=4), venous thrombosis (n=3), infectious cardiopathy (n=2), and ischemic stroke (n=2). This description of serious cardiovascular outcomes in prisoners who use cannabis provides insights into the clinical features possibly observed in this vulnerable population The findings indicate that 7.5% of hospitalizations of prisoners for cardiovascular disorders are potentially linked to cannabis used in prison.

Identifiants

pubmed: 32718583
pii: S0040-5957(20)30125-6
doi: 10.1016/j.therap.2020.06.017
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

579-589

Informations de copyright

Copyright © 2020 Société française de pharmacologie et de thérapeutique. Published by Elsevier Masson SAS. All rights reserved.

Auteurs

Marion Mongiatti (M)

Forensic medicine and medicine in prison environment department, inter-regional secured hospital unit, Toulouse Rangueil university hospital, 31059 Toulouse, France.

Paule Bayle (P)

Forensic medicine and medicine in prison environment department, inter-regional secured hospital unit, Toulouse Rangueil university hospital, 31059 Toulouse, France.

Aude Lagarrigue (A)

Forensic medicine and medicine in prison environment department, inter-regional secured hospital unit, Toulouse Rangueil university hospital, 31059 Toulouse, France.

Dider Fabre (D)

Department of medical information, Toulouse university hospital, Hôtel-Dieu Saint-Jacques, 31059 Toulouse, France.

Norbert Telmon (N)

Forensic medicine and medicine in prison environment department, inter-regional secured hospital unit, Toulouse Rangueil university hospital, 31059 Toulouse, France; AMIS (molecular anthropology and synthesis imagery) laboratory, CNRS 5588, university of Toulouse, 31059 Toulouse, France.

Maryse Lapeyre-Mestre (M)

Pharmacoepidemiology research team, INSERM 1027, university of Toulouse, 31000 Toulouse, France; Addictovigilance center, department of medical and clinical pharmacology, Toulouse university hospital, 31000 Toulouse, France.

Emilie Jouanjus (E)

Pharmacoepidemiology research team, INSERM 1027, university of Toulouse, 31000 Toulouse, France; Addictovigilance center, department of medical and clinical pharmacology, Toulouse university hospital, 31000 Toulouse, France. Electronic address: emilie.jouanjus@univ-tlse3.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH